放射配體治療市場報告：趨勢、預測和競爭分析（至 2030 年）

放射配體治療的趨勢和預測

全球放射配體治療市場未來性，醫院/診所和診斷中心市場充滿機會。預計到 2030 年，全球放射配體治療市場將達到約 138 億美元，2024 年至 2030 年的複合年成長率為 5.0%。該市場的主要促進因素是癌症發病率的上升和對有效治療的高需求。

• 在同位素類別中，Lucintel 預計，由於癌症診斷的高需求，氟 18 在預測期內仍將是最大的部分。
• 在最終用途類別中，由於久坐生活方式的盛行和全球癌症患者數量的不斷增加，醫院仍然是最大的部分。
• 從地區來看，由於專門的癌症醫院和研究中心的存在以及全部區域的癌症發病率上升，預計北美在預測期內仍將是最大的地區。

放射配體治療市場的策略性成長機會

由於技術進步和癌症治療中標標靶治療的接受度不斷提高，放射配體治療市場提供了各種機會。利用這些機會將帶來業務進步和市場擴張。

• 前列腺癌治療：由於前列腺癌的發生率不斷上升，Pluvicto 等標靶治療療法繼續受到歡迎。我們在這一領域的研發活動和業務的進一步擴展提供了巨大的成長機會，同時滿足了對更有效治療的需求。
• 神經內分泌腫瘤：由於監管和市場開拓的成功，神經內分泌腫瘤放射性配體治療的預後診斷方法已被證明能夠進一步開發和商業化。這個機會透過擴大目標人群來縮小公司的收益差距。
• 聯合治療：將放射配體治療與免疫治療和化療結合可以使治療更有效、更持久，並且可以避免抗藥性。這為研究和市場成長提供了新的機會，使患者和治療方法都受益。
• 新興市場：潛在市場中放射性配體療法的出現是為了滿足對先進藥物療法不斷成長的需求。這一機會將有助於擴大全球市場規模並提供接觸新病患小組的機會。
• 先進影像的整合：透過整合PET、SPECT等先進成像技術，放射配體治療在治療精度和控制方面可以顯著提高。這一機會透過提供更好的治療選擇來促進市場成長。

前列腺癌、神經內分泌腫瘤、聯合治療、新興市場和先進的影像整合具有策略性的市場成長機會，可以利用這些機會來促進市場成長。這些機會推動了放射配體治療市場的潛在擴張和技術進步。

放射配體治療市場的促進因素與挑戰

放射配體治療市場指南由多個監管、技術和經濟促進因素和挑戰決定。解決這些因素對於市場成長和創新至關重要。

放射配體治療市場的促進因素

• 技術進步：隨著新技術的發展，放射配體治療變得更加有效和準確。新製造流程和先進成像技術的發現將透過提高治療效果和擴大放射性配體治療範圍來促進市場成長。
• 癌症診斷的增加：癌症發生率的增加增加了對標靶治療的需求。癌症發生率的增加將加速先進放射性配體療法的商業化，並支持進一步的研究和開發，以滿足未滿足的醫療需求。
• 某些藥物的監管核准：加速新治療方法的監管核准簡化了新放射性配體療法的開發和引入。這個過程透過促進治療開發的理想結果來促進市場成長。
• 增加研發投資：放射配體治療的進步是由公司許多合作的努力所推動的。這種合作加強了研究和開發，帶來新的提案和更有效的治療方法。
• 發展更有針對性的癌症治療方法：個人化醫療的發展使得針對個別患者的放射性配體療法的開發成為可能。這可以透過滿足特定患者的需求來改善治療效果並擴大市場。

放射配體治療市場挑戰

• 開發成本高：開發新的治療方法和技術可能成本高並阻礙進展。成本管理和投資規劃對於企業保持競爭力至關重要。
• 監理障礙：遵守藥品法規既困難又耗時。公司需要隨時了解不斷變化的法規，以加快新治療方法的核准流程。
• 市場競爭：市場競爭會影響市場佔有率和利潤。公司必須創新以保持競爭力，提供強力的臨床證據，並與夥伴關係提高其市場地位。

放射配體治療市場受到技術進步、癌症發生率增加、監管核准、研發投資以及個人化醫療趨勢的推動。然而，為了確保成長和創新，必須解決高昂的開發成本、監管障礙和市場競爭。

目錄

第1章執行摘要

第2章全球放射配體治療市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 市場趨勢及預測分析（2018-2030）

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球放射配體治療市場趨勢（2018-2023）與預測（2024-2030）
• 全球放射配體治療市場：依同位素
  • 氟18
  • 鎵68
  • 鎦-177
  • 其他
• 全球放射配體治療市場：按目標受體
  • 攝護腺特異性膜抗原
  • 生長抑制素受體
  • 表皮生長因子受體
  • 其他
• 全球放射配體治療市場：依適應症分類
  • 攝護腺癌
  • 神經內分泌腫瘤
  • 乳癌
  • 其他
• 全球放射配體治療市場：依最終用途分類
  • 醫院/診所
  • 診斷中心
  • 其他

第4章 各地區市場趨勢及預測分析（2018-2030）

• 全球放射配體治療市場：按地區
• 北美放射配體治療市場
• 歐洲放射配體治療市場
• 亞太地區放射配體治療市場
• 其他地區放射配體治療市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球放射配體治療市場成長機會：依同位素
  • 全球放射配體治療市場成長機會：按目標受體
  • 全球放射配體治療市場成長機會：依跡象分類
  • 全球放射配體治療市場成長機會：依最終用途分類
  • 全球放射配體治療市場成長機會：按地區
• 全球放射配體治療市場的新興趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球放射配體治療市場的產能
  • 全球放射配體治療市場的企業合併
  • 認證和許可

第7章主要企業簡介

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy Trends and Forecast

The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinics and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and the high demand for effective treatment.

• Lucintel forecasts that, within the isotope category, fluorine-18 will remain the largest segment over the forecast period due to the high demand for cancer diagnosis.
• Within this end-use category, hospitals will remain the largest segment due to the increasing prevalence of a sedentary lifestyle and the growing cases of cancer globally.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of specialized cancer hospitals and research centers, as well as the rising incidences of cancer across the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Radioligand Therapy Market

The radioligand therapy market underscores the changes brought about by technology, clinical development, and patient treatment. These trends are transforming the landscape of chemotherapy and broadening the range of indications for radioligand therapies.

• Increased Focus on Personalized Medicine: Tailoring the pharmacological agents used in radioligand therapy to the patient's tumor markers and genetic makeup adds another dimension to the personalized medicine aspect of radioligand therapy. This also leads to better responses and fewer side effects, which promote the use of personalized therapies, thereby increasing the market potential for such therapies.
• Progress in Radiopharmaceutical Manufacturing: Increases in automation and better radiolabeling technologies make these production processes more efficient and amenable to scaling up, increasing the availability of radioligand therapies for patients. Such advancements meet the increasing market need for quality radiopharmaceuticals and simplify treatment procedures.
• Increase in Clinical Trials and Research: The expansion of clinical trials enhances the discovery of new treatments with radioligands as well as new markets for older drugs. Innovations and contributions toward radioligand therapy, anchored in evidence-based research, increase penetration and acceptance of the therapy in the market and among the population at large.
• Use of Other Imaging Approaches: Advanced imaging techniques, such as combining SPECT or PET with radioligands, enable researchers to monitor responses and locate cancer sites in real-time during the course of therapy, enhancing the accuracy of radioligand therapies. This trend improves patient management and outcomes as it increases treatment accuracy and, therefore, efficacy.
• Improvement in International Networking and Cooperation: With the central goal of optimizing research and clinical development of radioligand therapies, global partnerships enhance the movement of knowledge, resources, and technologies. The benefits of these collaborations include access to know-how and creativity, which fosters market development and increases the availability of new therapies.

The emerging themes of personalized medicine, new frontiers in radiopharmaceutical production, clinical research expansion, incorporation with imaging, and international collaborations are game-changers in the radioligand therapy market. These trends stimulate development, increase efficacy, and elevate the feasibility of targeted cancer treatment options.

Recent Developments in the Radioligand Therapy Market

The recent developments in radioligand therapy, which also include commercialization activities, emphasize technological advancements, clinical application patterns, and marketing trends. These developments create avenues for new research and further descriptive development of radioligand therapy in the management of localized cancer.

• FDA Approvals of Novel Therapies: This will broaden the scope of available therapies for patients suffering from neuroendocrine tumors and prostate cancer. It also opens up new market avenues and facilitates the innovation process in radioligand therapy by increasing the types of treatments available.
• Development of New Procedures for the Production of Radiopharmaceuticals: Advances in production technology contribute to the optimal utilization and bulk production of radiopharmaceuticals. These improvements benefit the expansion of the market, where the demand for higher-quality radioligand therapies continues to grow.
• Broadening of Clinical Trials: Expanding the scope of clinical trials accelerates the formulation of medicines and substantiates the claims made about current medications. This development enables further market growth through research and improvement of therapy modalities.
• Inclusion of Improved Imaging Techniques: The use of advanced imaging techniques adds to the accuracy and effectiveness of radioligand therapies. In this development, treatment response and tumor localization during treatment are monitored, improving patient management and outcomes.
• Collaborations and Partnerships Around the Globe: Partnerships help pool skills and assets, which in turn accelerate the development and marketing of radioligand therapies. These collaborations consolidate the global market and encourage creativity by working together.

In the last one and a half years, advances in FDA approvals, production, clinical trials, incorporation of imaging, and international collaborations have greatly influenced the radioligand therapy market. These advancements foster innovation, improve treatment effectiveness, and increase the potential for commercialization of products, thus defining future targeted cancer therapies.

Strategic Growth Opportunities for Radioligand Therapy Market

The radioligand therapy market presents various opportunities due to technological advancements and the growing acceptance of targeted therapy for cancer treatment. Taking advantage of these opportunities will help in business advancement and market expansion.

• Prostate Cancer Treatment: Targeted treatments like Pluvicto continue to gain traction due to the increasing incidence rates of prostate cancer. Further expansion of R&D activities and a larger footprint in this area present significant growth opportunities while addressing the need for more effective treatments.
• Neuroendocrine Tumors: Successful regulation and market access demonstrate that theragnostic approaches for radioligand therapy in neuroendocrine tumors can be further developed and marketed. This opportunity fills revenue gaps for businesses by expanding target populations.
• Combination Therapies: Combining radioligand therapies with immunotherapy or chemotherapy could make treatment more effective and lasting while avoiding resistance. This offers new opportunities for research and market growth, benefiting both patients and their treatments.
• Emerging Markets: The emergence of radioligand therapies in latent markets meets the increasing demand for advanced medication. This opportunity helps expand the size of the global market and provides access to new patient groups.
• Advanced Imaging Integration: Radioligand therapies are significantly improved in terms of treatment accuracy and management by incorporating advanced imaging techniques, such as PET and SPECT. This opportunity achieves market growth by providing better treatment options.

There are strategic market growth opportunities in prostate cancer, neuroendocrine tumors, combination therapies, emerging markets, and advanced imaging integration that can be exploited for market growth. These opportunities encourage potential expansion and technology enhancement in the radioligand therapy market.

Radioligand Therapy Market Driver and Challenges

The guiding factors for the radioligand therapy market are defined by several regulatory, technological, and economic drivers and challenges. Addressing these factors is essential for growth and innovation in the marketplace.

Drivers of the Radioligand Therapy Market:

• Technological Advancements: As new techniques are developed, radioligand therapies become more efficient and accurate. The discovery of new production processes and advanced imaging techniques improves treatment efficacy and contributes to market growth by broadening the scope of radioligand therapies.
• Increasing Cancer Diagnoses: The rising prevalence of cancer enhances the demand for targeted therapies. The growing incidence of cancer accelerates the commercialization of advanced radioligand therapies and supports further research and development to meet unmet medical needs.
• Regulatory Approvals for Certain Drugs: Faster regulatory approvals for new therapies help streamline the development and introduction of new radioligand treatments. This process fosters market growth by promoting the desired outcomes in treatment development.
• Increased Investment in R&D: Many collaborative efforts by companies have contributed to advancements in radioligand therapy. These collaborations enhance research and development, leading to proposed new applications and more efficient treatments.
• Development of More Targeted Treatments for Cancer: The movement toward personalized medicine is enabling the development of radioligand therapies for individual patients. This improves treatment outcomes and helps expand the market by meeting the specific needs of patients.

Challenges in the Radioligand Therapy Market:

• High Development Costs: The high costs associated with developing new therapies and technologies may hinder progress. Cost control and investment planning are essential for companies to stay competitive.
• Regulatory Roadblocks: Navigating regulatory requirements can be challenging and time-consuming. Companies must stay updated on evolving regulations to expedite approval processes for new therapies.
• Market Competition: Competition in the market may impact market share and profits. Companies must innovate and provide strong clinical evidence to stay ahead of the competition and engage in partnerships that enhance their market position.

The radioligand therapy market is driven by technological advancements, increasing cancer prevalence, regulatory approvals, R&D investment, and trends toward personalized medicine. However, high development costs, regulatory hurdles, and market competition must be addressed to ensure growth and innovation.

List of Radioligand Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-

• Novartis
• POINT Biopharma Global
• Molecular Partners
• Telix Pharmaceuticals
• Fusion Pharma
• Lantheus Holdings
• Curium
• Precrix
• Orano
• Artios Pharma

Radioligand Therapy by Segment

The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.

Radioligand Therapy Market by Isotope [Analysis by Value from 2018 to 2030]:

• Fluorine - 18
• Gallium - 68
• Lutetium - 177
• Others

Radioligand Therapy Market by Targeted Receptor [Analysis by Value from 2018 to 2030]:

• Prostate-Specific Membrane Antigen
• Somatostatin Receptor
• Epidermal Growth Factor Receptor
• Others

Radioligand Therapy Market by Indication [Analysis by Value from 2018 to 2030]:

• Prostate Cancer
• Neuroendocrine Tumors
• Breast Cancer
• Others

Radioligand Therapy Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Diagnostic Centers
• Others

Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Radioligand Therapy Market

Recent developments in the radioligand therapy market include advances in technology, registration, and clinical practice. The growing trend among patients toward personalized medicine and targeted techniques is filling the gap created by recent activity in the field of radioligand therapies in countries like the United States, China, Germany, India, and Japan.

• United States: The US market for radioligand therapy is growing rapidly due to new FDA treatment approvals and the expansion of clinical trials. Recent developments include the release of promising drugs, such as Lutathera for treating neuroendocrine tumors and Pluvicto for treating prostate cancer. There is also a focus on improving technologies for radiopharmaceutical production and exploring new therapy combinations to improve treatment efficacy.
• China: China is making significant progress in radioligand treatment, focusing on building a local manufacturing base and expanding clinical trials. Recently, partnerships have been formed between Chinese pharmaceutical companies and international firms to develop new radioligand products. The country is also implementing regulatory schemes to facilitate approvals for radioligand therapies to meet the growing demand for tailored cancer treatments.
• Germany: Germany remains a leader in the radioligand therapy market, making continuous strides in research and development. German institutions are involved in clinical trials for new therapeutic radioligands targeting various cancers, including prostate and neuroendocrine tumors. The country is also enhancing its radiopharmaceutical manufacturing infrastructure and improving treatment control using advanced imaging techniques.
• India: The radioligand therapy market in India is evolving as the population becomes more engaged in oncology and personalized medicine. Clinical trials focusing on new radioligand therapies and global partnerships with research institutions have been established. The focus is on increasing the availability of new radiopharmaceuticals and expanding the use of existing ones to meet the growing patient pool.
• Japan: Japan is also progressing in the radioligand therapy market, with new treatment approvals and technological innovations. Japanese oncology organizations are developing new radioligand therapies and improving production technologies for both domestic use and export. The country is also increasing funding for research to find more indications and enhance existing treatments.

Features of the Global Radioligand Therapy Market

Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).

Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the radioligand therapy market by isotope (fluorine - 18, gallium - 68, lutetium - 177, and others), targeted receptor (prostate-specific membrane antigen, somatostatin receptor, epidermal growth factor receptor, and others), indication (prostate cancer, neuroendocrine tumors, breast cancer, and others), end use (hospitals & clinics, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radioligand Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Radioligand Therapy Market by Isotope
  • 3.3.1: Fluorine - 18
  • 3.3.2: Gallium - 68
  • 3.3.3: Lutetium - 177
  • 3.3.4: Others
• 3.4: Global Radioligand Therapy Market by Targeted Receptor
  • 3.4.1: Prostate-specific Membrane Antigen
  • 3.4.2: Somatostatin Receptor
  • 3.4.3: Epidermal Growth Factor Receptor
  • 3.4.4: Others
• 3.5: Global Radioligand Therapy Market by Indication
  • 3.5.1: Prostate Cancer
  • 3.5.2: Neuroendocrine Tumors
  • 3.5.3: Breast Cancer
  • 3.5.4: Others
• 3.6: Global Radioligand Therapy Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Diagnostic Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Radioligand Therapy Market by Region
• 4.2: North American Radioligand Therapy Market
  • 4.2.1: North American Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.3: European Radioligand Therapy Market
  • 4.3.1: European Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.4: APAC Radioligand Therapy Market
  • 4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
• 4.5: ROW Radioligand Therapy Market
  • 4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
  • 4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
  • 6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
  • 6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
  • 6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
  • 6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
• 6.2: Emerging Trends in the Global Radioligand Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: POINT Biopharma Global
• 7.3: Molecular Partners
• 7.4: Telix Pharmaceuticals
• 7.5: Fusion Pharma
• 7.6: Lantheus Holdings
• 7.7: Curium
• 7.8: Precrix
• 7.9: Orano
• 7.10: Artios Pharma